Prostate cancer theranostics with 177Lu-PSMA
This review paper highlights the transformative role of PSMA-targeted diagnostics and therapy in prostate cancer management, particularly focusing on 177Lu-PSMA-617, approved by the FDA and EMA for metastatic castration-resistant prostate cancer (mCRPC) patients post-chemotherapy and ARPI treatment....
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2024
|
| In: |
Seminars in nuclear medicine
Year: 2024, Jahrgang: 54, Heft: 4, Pages: 581-590 |
| ISSN: | 1558-4623 |
| DOI: | 10.1053/j.semnuclmed.2024.02.007 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1053/j.semnuclmed.2024.02.007 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0001299824000242 
|
| Verfasserangaben: | Hojjat Ahmadzadehfar, Robert Seifert, Ali Afshar-Oromieh, Clemens Kratochwil, and Kambiz Rahbar |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1930421656 | ||
| 003 | DE-627 | ||
| 005 | 20250714110845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250714s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.semnuclmed.2024.02.007 |2 doi | |
| 035 | |a (DE-627)1930421656 | ||
| 035 | |a (DE-599)KXP1930421656 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ahmadzadehfar, Hojjat |d 1973- |e VerfasserIn |0 (DE-588)143484060 |0 (DE-627)646572075 |0 (DE-576)337312508 |4 aut | |
| 245 | 1 | 0 | |a Prostate cancer theranostics with 177Lu-PSMA |c Hojjat Ahmadzadehfar, Robert Seifert, Ali Afshar-Oromieh, Clemens Kratochwil, and Kambiz Rahbar |
| 246 | 3 | 3 | |a Prostate cancer theranostics with 177 Lu-PSMA |
| 264 | 1 | |c July 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 4. April 2024, Artikelversion: 1. August 2024 | ||
| 500 | |a Im Titel ist die Zahl 177 hochgestellt | ||
| 500 | |a Gesehen am 14.07.2025 | ||
| 520 | |a This review paper highlights the transformative role of PSMA-targeted diagnostics and therapy in prostate cancer management, particularly focusing on 177Lu-PSMA-617, approved by the FDA and EMA for metastatic castration-resistant prostate cancer (mCRPC) patients post-chemotherapy and ARPI treatment. Originating from the VISION trial's success, this paper navigates the current radioligand therapy (RLT) indications, emphasizing practical patient selection, planning, and treatment execution. It critically examines Lu-PSMA's comparative effectiveness against cabazitaxel and Ra-223, addressing decision-making dilemmas for mCRPC treatments. Furthermore, the paper discusses Lu-PSMA in chemotherapy-naïve patients and its application in hormone-sensitive prostate cancer, underlined by ongoing global studies. A significant concern is Lu-PSMA's long-term safety profile, particularly nephrotoxicity risks, necessitating further investigation. The possibility of Lu-PSMA rechallenge in responsive patients is explored, stressing the need for comprehensive analyses and real-world data to refine treatment protocols. Conclusively, PSMA-targeted therapy marks a significant advance in prostate cancer therapy, advocating for its integration into a multimodal, patient-centric treatment approach. The review underscores the imperative for additional comparative studies to optimize treatment sequences and outcomes, ultimately enhancing long-term prognosis and disease control in prostate cancer management. | ||
| 700 | 1 | |a Seifert, Robert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Afshar-Oromieh, Ali |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kratochwil, Clemens |d 1978- |e VerfasserIn |0 (DE-588)134026276 |0 (DE-627)559871686 |0 (DE-576)300262787 |4 aut | |
| 700 | 1 | |a Rahbar, Kambiz |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in nuclear medicine |d New York, NY [u.a.] : Elsevier, 1971 |g 54(2024), 4 vom: Juli, Seite 581-590 |h Online-Ressource |w (DE-627)378128027 |w (DE-600)2133379-8 |w (DE-576)121466868 |x 1558-4623 |7 nnas |a Prostate cancer theranostics with 177Lu-PSMA |
| 773 | 1 | 8 | |g volume:54 |g year:2024 |g number:4 |g month:07 |g pages:581-590 |g extent:10 |a Prostate cancer theranostics with 177Lu-PSMA |
| 856 | 4 | 0 | |u https://doi.org/10.1053/j.semnuclmed.2024.02.007 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0001299824000242 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250714 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 134026276 |a Kratochwil, Clemens |m 134026276:Kratochwil, Clemens |d 910000 |d 911400 |e 910000PK134026276 |e 911400PK134026276 |k 0/910000/ |k 1/910000/911400/ |p 4 | ||
| 999 | |a KXP-PPN1930421656 |e 4745974167 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Ahmadzadehfar, Hojjat","given":"Hojjat","role":"aut","family":"Ahmadzadehfar"},{"role":"aut","given":"Robert","family":"Seifert","display":"Seifert, Robert"},{"display":"Afshar-Oromieh, Ali","given":"Ali","role":"aut","family":"Afshar-Oromieh"},{"display":"Kratochwil, Clemens","role":"aut","given":"Clemens","family":"Kratochwil"},{"role":"aut","given":"Kambiz","family":"Rahbar","display":"Rahbar, Kambiz"}],"title":[{"title":"Prostate cancer theranostics with 177Lu-PSMA","title_sort":"Prostate cancer theranostics with 177Lu-PSMA"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"noteIll":"Illustrationen","extent":"10 S."}],"language":["eng"],"id":{"doi":["10.1053/j.semnuclmed.2024.02.007"],"eki":["1930421656"]},"origin":[{"dateIssuedDisp":"July 2024","dateIssuedKey":"2024"}],"name":{"displayForm":["Hojjat Ahmadzadehfar, Robert Seifert, Ali Afshar-Oromieh, Clemens Kratochwil, and Kambiz Rahbar"]},"recId":"1930421656","titleAlt":[{"title":"Prostate cancer theranostics with 177 Lu-PSMA"}],"note":["Online verfügbar: 4. April 2024, Artikelversion: 1. August 2024","Im Titel ist die Zahl 177 hochgestellt","Gesehen am 14.07.2025"],"relHost":[{"title":[{"title":"Seminars in nuclear medicine","title_sort":"Seminars in nuclear medicine"}],"pubHistory":["1.1971 -"],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 16.03.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"pages":"581-590","volume":"54","extent":"10","text":"54(2024), 4 vom: Juli, Seite 581-590","year":"2024","issue":"4"},"origin":[{"publisherPlace":"New York, NY [u.a.] ; Duluth, Minn.","dateIssuedKey":"1971","publisher":"Elsevier ; Saunders","dateIssuedDisp":"1971-"}],"id":{"eki":["378128027"],"issn":["1558-4623"],"zdb":["2133379-8"]},"disp":"Prostate cancer theranostics with 177Lu-PSMASeminars in nuclear medicine","recId":"378128027"}]} | ||
| SRT | |a AHMADZADEHPROSTATECA2024 | ||